Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2017

Open Access 01-12-2017 | Research article

α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis

Authors: Yosuke Kanno, En Shu, Hiroyuki Kanoh, Ayaka Matsuda, Mariko Seishima

Published in: Arthritis Research & Therapy | Issue 1/2017

Login to get access

Abstract

Background

Systemic sclerosis (SSc) is a connective tissues disease of unknown origin characterized by vascular damage and extensive fibrosis. Recently, we demonstrated that α2-antiplasmin (α2AP) is associated with the development of fibrosis in SSc. We herein investigate the roles of α2AP in vascular dysfunction in SSc.

Methods

Vascular damage in mice was determined by the levels of blood vessels and blood flow. Vascular functions in vascular endothelial cells (ECs) were determined by the levels of tube formation, cell proliferation, and endothelial junction-associated protein (VE-cadherin and PECAM1) production.

Results

The administration of α2AP induced vascular damage in mice. Conversely, the α2AP neutralization improved vascular damage in a bleomycin-induced mouse model of SSc. Additionally, we showed that the SSc fibroblast-conditioned media induced the reduction of tube formation, cell proliferation, and endothelial junction-associated protein production in ECs, and that α2AP neutralization improved them. We also examined the mechanisms underlying the effects of α2AP on vascular alteration in SSc and found that α2AP attenuated vascular endothelial growth factor-induced tube formation, cell proliferation, and endothelial junction-associated protein production through the adipose triglyceride lipase/tyrosine phosphatase SHP2 axis in ECs.

Conclusion

Our findings demonstrate that α2AP is associated with vascular alteration, and that the blocking of α2AP improves vascular dysfunction in SSc.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev. 2011;10:590–4.CrossRefPubMed Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev. 2011;10:590–4.CrossRefPubMed
3.
go back to reference Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 2010;6:453–60.CrossRefPubMed Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 2010;6:453–60.CrossRefPubMed
4.
go back to reference Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69:209–16.CrossRefPubMed Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69:209–16.CrossRefPubMed
5.
go back to reference Menoud PA, Sappino N, Boudal-Khoshbeen M, Vassalli JD, Sappino AP. The kidney is a major site of alpha(2)-antiplasmin production. J Clin Invest. 1996;97:2478–84.CrossRefPubMedPubMedCentral Menoud PA, Sappino N, Boudal-Khoshbeen M, Vassalli JD, Sappino AP. The kidney is a major site of alpha(2)-antiplasmin production. J Clin Invest. 1996;97:2478–84.CrossRefPubMedPubMedCentral
6.
go back to reference Kanno Y, Kuroki A, Okada K, Tomogane K, Ueshima S, Matsuo O, et al. alpha2-Antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis. J Thromb Haemost. 2007;5:2266–73.CrossRefPubMed Kanno Y, Kuroki A, Okada K, Tomogane K, Ueshima S, Matsuo O, et al. alpha2-Antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis. J Thromb Haemost. 2007;5:2266–73.CrossRefPubMed
7.
go back to reference Kanno Y, Kawashita E, Minamida M, Kaneiwa A, Okada K, Ueshima S, et al. alpha2-antiplasmin is associated with the progression of fibrosis. Am J Pathol. 2010;176:238–45.CrossRefPubMedPubMedCentral Kanno Y, Kawashita E, Minamida M, Kaneiwa A, Okada K, Ueshima S, et al. alpha2-antiplasmin is associated with the progression of fibrosis. Am J Pathol. 2010;176:238–45.CrossRefPubMedPubMedCentral
8.
go back to reference Kanno Y, Kawashita E, Kokado A, Okada K, Ueshima S, Matsuo O, et al. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2). Arthritis Rheum. 2013;65:492–502.CrossRefPubMed Kanno Y, Kawashita E, Kokado A, Okada K, Ueshima S, Matsuo O, et al. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2). Arthritis Rheum. 2013;65:492–502.CrossRefPubMed
9.
go back to reference Kanno Y, Kawashita E, Kokado A, Kuretake H, Ikeda K, Okada K, et al. α2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction. Sci Rep. 2014;4:5967.CrossRefPubMed Kanno Y, Kawashita E, Kokado A, Kuretake H, Ikeda K, Okada K, et al. α2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction. Sci Rep. 2014;4:5967.CrossRefPubMed
10.
go back to reference Kanno Y, Shu E, Kanoh H, Seishima M. The antifibrotic effect of α2AP neutralization in systemic sclerosis dermal fibroblasts and mouse models of systemic sclerosis. J Invest Dermatol. 2016;136:762–9.CrossRefPubMed Kanno Y, Shu E, Kanoh H, Seishima M. The antifibrotic effect of α2AP neutralization in systemic sclerosis dermal fibroblasts and mouse models of systemic sclerosis. J Invest Dermatol. 2016;136:762–9.CrossRefPubMed
11.
go back to reference Kanno Y, Hirade K, Ishisaki A, Nakajima K, Suga H, Into T, et al. Lack of alpha2-antiplasmin improves cutaneous wound healing via over-released vascular endothelial growth factor-induced angiogenesis in wound lesions. J Thromb Haemost. 2006;4:1602–10.CrossRefPubMed Kanno Y, Hirade K, Ishisaki A, Nakajima K, Suga H, Into T, et al. Lack of alpha2-antiplasmin improves cutaneous wound healing via over-released vascular endothelial growth factor-induced angiogenesis in wound lesions. J Thromb Haemost. 2006;4:1602–10.CrossRefPubMed
12.
go back to reference Hou Y, Okada K, Okamoto C, Ueshima S, Matsuo O. Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1257–62.CrossRefPubMed Hou Y, Okada K, Okamoto C, Ueshima S, Matsuo O. Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1257–62.CrossRefPubMed
13.
go back to reference Fraineau S, Monvoisin A, Clarhaut J, Talbot J, Simonneau C, Kanthou C, et al. The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner. Blood. 2012;120:5073–83.CrossRefPubMed Fraineau S, Monvoisin A, Clarhaut J, Talbot J, Simonneau C, Kanthou C, et al. The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner. Blood. 2012;120:5073–83.CrossRefPubMed
14.
go back to reference Zhabin SG, Gorin VS. The effects of alpha 2-antiplasmin complex and alpha 2-antiplasmin on the secretion of IgG and IgM by cultured human mononuclear cells. J Clin Lab Immunol. 1997;49:77–82.PubMed Zhabin SG, Gorin VS. The effects of alpha 2-antiplasmin complex and alpha 2-antiplasmin on the secretion of IgG and IgM by cultured human mononuclear cells. J Clin Lab Immunol. 1997;49:77–82.PubMed
15.
go back to reference Okada K, Ueshima S, Kawao N, Yano M, Tamura Y, Tanaka M, et al. Lack of both α2-antiplasmin and plasminogen activator inhibitor type-1 induces high IgE production. Life Sci. 2013;93:89–95.CrossRefPubMed Okada K, Ueshima S, Kawao N, Yano M, Tamura Y, Tanaka M, et al. Lack of both α2-antiplasmin and plasminogen activator inhibitor type-1 induces high IgE production. Life Sci. 2013;93:89–95.CrossRefPubMed
16.
go back to reference Kager LM, Weehuizen TA, Wiersinga WJ, Roelofs JJ, Meijers JC, Dondorp AM, et al. Endogenous α2-antiplasmin is protective during severe gram-negative sepsis (melioidosis). Am J Respir Crit Care Med. 2013;188:967–75.CrossRefPubMed Kager LM, Weehuizen TA, Wiersinga WJ, Roelofs JJ, Meijers JC, Dondorp AM, et al. Endogenous α2-antiplasmin is protective during severe gram-negative sepsis (melioidosis). Am J Respir Crit Care Med. 2013;188:967–75.CrossRefPubMed
17.
go back to reference Eddy JL, Schroeder JA, Zimbler DL, Bellows LE, Lathem WW. Impact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague. Infect Immun. 2015;83:4837–47.CrossRefPubMedPubMedCentral Eddy JL, Schroeder JA, Zimbler DL, Bellows LE, Lathem WW. Impact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague. Infect Immun. 2015;83:4837–47.CrossRefPubMedPubMedCentral
18.
19.
go back to reference Serratì S, Cinelli M, Margheri F, Guiducci S, Del Rosso A, Pucci M, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006;210:240–8.CrossRefPubMed Serratì S, Cinelli M, Margheri F, Guiducci S, Del Rosso A, Pucci M, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006;210:240–8.CrossRefPubMed
20.
go back to reference Plow EF, Hoover-Plow J. The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med. 2004;14:180–6.CrossRefPubMed Plow EF, Hoover-Plow J. The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med. 2004;14:180–6.CrossRefPubMed
21.
go back to reference Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K. Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. Rheumatology (Oxford). 2003;42:240–3.CrossRef Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K. Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. Rheumatology (Oxford). 2003;42:240–3.CrossRef
22.
go back to reference Marie I, Borg JY, Hellot MF, Levesque H. Plasma D-dimer concentration in patients with systemic sclerosis. Br J Dermatol. 2008;158:392–5.PubMed Marie I, Borg JY, Hellot MF, Levesque H. Plasma D-dimer concentration in patients with systemic sclerosis. Br J Dermatol. 2008;158:392–5.PubMed
Metadata
Title
α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis
Authors
Yosuke Kanno
En Shu
Hiroyuki Kanoh
Ayaka Matsuda
Mariko Seishima
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2017
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-017-1227-y

Other articles of this Issue 1/2017

Arthritis Research & Therapy 1/2017 Go to the issue